Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Employees

129

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	ILA 4,214.00	-2.45%	13,838
03/09/26	ILA 4,320.00	0.00%	54,132
02/09/26	ILA 4,320.00	+0.09%	33,028
01/09/26	ILA 4,316.00	-3.73%	84,090
31/08/26	ILA 4,483.00	+3.99%	140,329

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - TEL AVIV STOCK EXCHANGE 11:31:09 04/09/2026 BST			5-day change	1st Jan Change
4,214.00 ^ILa	-2.45%		-2.25%	+34.85%

08-31	Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO	MT
08-27	BrainsWay Ltd. Publishes Peer-Reviewed Data Demonstrating 70% Reduction in Suicidal Ideation with Deep TMS in Major Depressive Disorder	CI

Market Cap	578M 0 497M 466M 427M 796M 54.61B 803M 5.52B 2.15B 27.91B 2.17B 2.12B 89.87B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	578M 0 497M 466M 427M 796M 54.61B 803M 5.52B 2.15B 27.91B 2.17B 2.12B 89.87B	EV / Sales 2026 *	8.35x	EV / Sales 2027 *	6.77x
Free-Float	90.5%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
TEL AVIV STOCK EXCHANGE	BWAY	Delayed
OTC Markets	BRSYF	Delayed

08-31	Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO	MT
08-27	BrainsWay Ltd. Publishes Peer-Reviewed Data Demonstrating 70% Reduction in Suicidal Ideation with Deep TMS in Major Depressive Disorder	CI
08-12	BrainsWay Shares Rise After Higher Q2 Results	MT
08-12	BrainsWay Ltd., Q2 2026 Earnings Call, Aug 12, 2026
08-12	BrainsWay Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	BrainsWay Ltd. Raises Earnings Guidance for the Fiscal Year 2026	CI
07-20	Radial Health, S.C. announced that it has received $53 million in funding from a group of investors	CI
07-20	BTIG Initiates Brainsway at Buy With $18 Price Target	MT
07-16	Sound Minds Behavioral announced that it expects to receive $0.5 million in funding from BrainsWay Ltd.	CI
07-16	BrainsWay Announces Strategic Investment in Sound Minds Behavioral	MT
06-29	Brainsway Ltd. Presents Positive Data From Largest Real-World Study Of Deep TMS In Patients With Comorbid PTSD And Major Depressive Disorder	CI
06-09	BrainsWay Presents First SWIFT Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	CI
05-18	Hopemark Health, Ltd announced that it expects to receive funding from BrainsWay Ltd.	CI

BrainsWay Ltd. Share Price

Stocks

BWAY

IL0011007189

Advanced Medical Equipment & Technology

Valuation : BrainsWay Ltd.

Chart: BrainsWay Ltd.

Latest news : BrainsWay Ltd.

Last Transcript : BrainsWay Ltd.

Analysts' recommendations : BrainsWay Ltd.

Press Releases : BrainsWay Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : BrainsWay Ltd.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

07-20	BTIG Initiates Brainsway at Buy With $18 Price Target	MT
11-13	BrainsWay Ltd. Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents Aged 15 to 21	CI
14/05/25	Oppenheimer Adjusts Brainsway Price Target to $15 From $13, Maintains Outperform Rating	MT
09/05/24	Oppenheimer Adjusts Brainsway Price Target to $11 From $10, Maintains Outperform Rating	MT
09/05/24	HC Wainwright Adjusts Price Target on Brainsway to $15 From $13, Keeps Buy Rating	MT

08-27	BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation	AQ
08-12	BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights	AQ
07-29	BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026	AQ
07-20	BrainsWay Announces Strategic Investment in Radial Health, Inc.	AQ
07-16	BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral	AQ

1 day	-2.45%
1 week	-2.25%
Current month	-6.00%
1 month	-12.03%
3 months	+2.41%
6 months	+11.48%
Current year	+34.85%

1 week	4,153	4,483
1 month	4,153	5,075
Current year	3,080	5,165
1 year	2,391	5,165
3 years	631.1	5,165
5 years	272	5,165
10 years	272	5,165

Manager	Title	Age	Since
Hadar Levy CEO	Chief Executive Officer	54	12/02/2023
Yiftach Roth CTO	Chief Tech/Sci/R&D Officer	56	30/04/2006
Ido Marom DFI	Director of Finance/CFO	50	22/05/2023

Director	Title	Age	Since
David Zacut CHM	Chairman	74	31/12/2002
Avner Hagai BRD	Director/Board Member	70	31/10/2006
Abraham Zangen BRD	Director/Board Member	56	16/06/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/06/26	Yiftach Roth	Sell	Founder	-3,000	0.0075%
26/05/26	Eti Mitrany	Sell	Director	-7,980	0.0399%
20/05/26	Eti Mitrany	Exercice	Director	41,080	0.1026%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRAINSWAY LTD.	-2.45%	-2.25%	+60.53%	+556.18%	578M
THERMO FISHER SCIENTIFIC, INC.	+1.63%	-1.95%	+27.63%	+10.98%	229B
DANAHER CORPORATION	+0.53%	-2.16%	+5.81%	-20.54%	148B
INTUITIVE SURGICAL, INC.	-0.55%	+0.75%	-16.17%	+19.14%	131B
BOSTON SCIENTIFIC CORPORATION	-2.94%	+0.60%	-56.34%	-12.44%	68.04B
EDWARDS LIFESCIENCES CORPORATION	-1.15%	-0.19%	+10.54%	+17.54%	51.75B
SIEMENS HEALTHINEERS AG	+0.91%	-0.89%	-16.91%	-14.04%	50.21B
AGILENT TECHNOLOGIES, INC.	-0.93%	-4.89%	+19.77%	+23.03%	42.28B
WATERS CORPORATION	+0.33%	-1.83%	+42.58%	+47.16%	40.63B
RESMED, INC.	-0.73%	-2.79%	-14.87%	+43.97%	33.06B
Average	+0.01%	-1.19%	+6.26%	+67.10%	79.42B
Weighted average by Cap.	+0.73%	-1.78%	+3.83%	+7.54%

	2026 *	2027 *
Net sales	69.16M 0 59.51M 55.84M 51.09M 95.36M 6.54B 96.11M 661M 257M 3.34B 260M 254M 10.76B	85.33M 0 73.42M 68.9M 63.04M 118M 8.07B 119M 815M 317M 4.12B 320M 313M 13.28B
Net income	12.38M 0 10.65M 10M 9.15M 17.07M 1.17B 17.21M 118M 46.06M 598M 46.5M 45.49M 1.93B	20.96M 0 18.04M 16.93M 15.49M 28.91M 1.98B 29.13M 200M 77.98M 1.01B 78.73M 77.01M 3.26B
Net Debt	-	-